Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

Program Halt Seen As 'Hit' To Vaccine-Making Reputation

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.